PRL and pituitary gland adenoma: Therefore, to reduce drug-related side-effects, we started CAB + ANA with step reductions in CAB dose to 2 mg/week (-0.5 mg after 6 and 12 months), achieving a further reduction of PRL nadir to 18 μg/L, a shrinkage of the pituitary adenoma (up to 11 × 6x6mm) and a better tolerance of CAB.